New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT07156253

First seen Oct 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This early-stage study is testing a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (like ovarian or breast cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 participants will take part to see if the combination can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • FuDan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • FuDan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.